

Reviewers for 1993

We wish to acknowledge the important assistance we have received from many scientists who, along with the Editorial Board, have evaluated manuscripts submitted

for publication during 1993. All outside reviewers are listed in the December issue of *Psychiatry Research* (Volume 49, Number 3, 1993).

Author Index for 1993

- Abbruzzese, M. 50:45
Alliger, R. 50:283
Almas, M. 50:25
Andreasen, N.C. 50:283
Arndt, S. 50:283
Asarnow, R.F. 50:33
Bartzokis, G. 50:33
Bonfanti, A. 50:45, 50:89
Calabrese, G. 50:89
Calabrese, J. 50:77
Cardwell, D. 50:67
Chan, S. 50:143
Cohen, G. 50:283
Colombo, C. 50:45, 50:89
Coppola, R. 50:177
Cosyns, P. 50:77
Daniel, D.G. 50:177
DeCaria, C.M. 50:25, 50:143
Degreef, G. 50:193
DeLisi, L.E. 50:193
Devous, M.D., Sr. 50:233
Dierckx, R. 50:77
Dierks, T. 50:151
Eckardt, M.J. 50:101
Engel, R. 50:163
Ericson, K. 50:15
Eriksson, L. 50:15
Farde, L. 50:1
Fink, G. 50:93
Fredrikson, M. 50:15
Frölich, L. 50:151
Fukuda, H. 50:217
Fukui, S. 50:217
Fukuyama, H. 50:203
Giunta, R. 50:163
Granholm, E. 50:33
Grannemann, B.D. 50:233
Greitz, T. 50:15
Günther, W. 50:163
Gullion, C.M. 50:233
Haag, C. 50:163
Halldin, C. 50:1
Harris, G.J. 50:57
Heiss, W.-D. 50:93
Herholz, K. 50:93
Hilal, S. 50:143
Hindmarsh, T. 50:1
Hoff, A.L. 50:193
Hollander, E. 50:25, 50:143
Ihl, R. 50:151
Ingels, M. 50:77
Ishikura, S. 50:203
Itoh, T. 50:217
Iyo, M. 50:217
John, E.R. 50:25
Jonitz, L. 50:163
Joyce, E.M. 50:101
Karson, C.N. 50:67
Kato, T. 50:203
Klages, U. 50:163
Klein, D.F. 50:143
Koenig, T. 50:275
Komoroski, R.A. 50:67
Kushner, M. 50:193
Lehmann, D. 50:275
Levine, R.H. 50:25
Liebowitz, M. 50:25
Liebowitz, M.R. 50:143
Lim, K.O. 50:257
Litton, J.-E. 50:1
Livian, S. 50:45
Locatelli, M. 50:45
Maes, M. 50:77
Marder, S.R. 50:33
Mareco, S. 50:177
Mas, F. 50:25
Mathalon, D.H. 50:121, 50:257, 50:284
Maurer, K. 50:151
Meltzer, H.Y. 50:77
Michel, C.M. 50:275
Mielke, R. 50:93
Mohanakrishnan, P. 50:67

- Morita, R. 50:203
Narita, M. 50:203
Neiman, J. 50:1
Newton, J.E.O. 50:67
Nishio, M. 50:217
Ohnishi, H. 50:203
Pauli, S. 50:1
Pearlson, G.D. 50:57
Pfefferbaum, A. 50:121, 50:257, 50:284
Prichep, L.S. 50:25
Rawles, J.M. 50:121, 50:284
Rio, D.E. 50:101
Ritter, D. 50:93
Rosenblom, M.J. 50:257
Rush, A.J. 50:233
Ruttmann, U.E. 50:101
Satoh, K. 50:203
Satzger, W. 50:163
Scarone, S. 50:45, 50:89
Schotte, C. 50:77
Scotti, G. 50:45, 50:89
Sedvall, G. 50:1
Shear, P.K. 50:257
Shibasaki, M. 50:203
Sprigg, J.R. 50:67
Stein, D.J. 50:143
Steinberg, R. 50:163
Stone-Elander, S. 50:15
Sullivan, E.V. 50:121, 50:257, 50:284
Suzuki, K. 50:217
Suzuki, T. 50:203
Swayze, V.W. III 50:283
Takahashi, S. 50:203
Tateno, Y. 50:217
Trivedi, M.H. 50:233
Vandewoude, M. 50:77
Wackermann, J. 50:275
Weinberger, D.R. 50:177
Wik, G. 50:15
Yamasaki, T. 50:217
Zigun, J.R. 50:177

Subject Index for 1993

Affective disorder

- aging, regional cerebral blood flow, 50:233
aging, single photon emission computed tomography, 50:233
aging, unipolar depression, 50:233
frontal lobes, regional cerebral blood flow, 50:77
frontal lobes, single photon emission computed tomography, 50:77
frontal lobes, unipolar depression, 50:77
regional cerebral blood flow, aging, 50:233
regional cerebral blood flow, frontal lobes, 50:77
regional cerebral blood flow, unipolar depression, 50:77, 50:233
single photon emission computed tomography, aging, 50:233
single photon emission computed tomography, frontal lobes, 50:77
single photon emission computed tomography, unipolar depression, 50:77, 50:233
unipolar depression, aging, 50:233
unipolar depression, frontal lobes, 50:77
unipolar depression, regional cerebral blood flow, 50:77, 50:233
unipolar depression, single photon emission computed tomography, 50:77, 50:233

Aging

- affective disorder, regional cerebral blood flow, 50:233
affective disorder, single photon emission computed tomography, 50:233
alcohol dependence, cerebrospinal fluid volume, 50:257
alcohol dependence, computed tomography, 50:257
alcohol dependence, magnetic resonance imaging, 50:257
alcohol dependence, ventricle-brain ratio, 50:257
Alzheimer's disease, dipole analysis, 50:151
Alzheimer's disease, electroencephalography, 50:151, 50:163
Alzheimer's disease, motor performance, 50:163
Alzheimer's disease, music perception, 50:163
Alzheimer's disease, spectral analysis, 50:151
Alzheimer's disease, temporal lobes, 50:163
basal ganglia, frontal lobes, 50:93
basal ganglia, myotonic dystrophy, 50:93
basal ganglia, positron emission tomography, 50:93
cerebrospinal fluid volume, alcohol dependence, 50:257

Aging continued

- cerebrospinal fluid volume, computed tomography, 50:257
cerebrospinal fluid volume, magnetic resonance imaging, 50:257
cerebrospinal fluid volume, ventricle-brain ratio, 50:257
computed tomography, alcohol dependence, 50:257
computed tomography, cerebrospinal fluid volume, 50:257
computed tomography, magnetic resonance imaging, 50:257
computed tomography, ventricle-brain ratio, 50:257
dipole analysis, Alzheimer's disease, 50:151
dipole analysis, electroencephalography, 50:151
dipole analysis, spectral analysis, 50:151
electroencephalography, Alzheimer's disease, 50:151, 163
electroencephalography, dipole analysis, 50:151
electroencephalography, motor performance, 50:163
electroencephalography, music perception, 50:163
electroencephalography, spectral analysis, 50:151
electroencephalography, temporal lobes, 50:163
frontal lobes, basal ganglia, 50:93
frontal lobes, myotonic dystrophy, 50:93
frontal lobes, positron emission tomography, 50:93
magnetic resonance imaging, alcohol dependence, 50:257
magnetic resonance imaging, cerebrospinal fluid volume, 50:257
magnetic resonance imaging, computed tomography, 50:257
magnetic resonance imaging, ventricle-brain ratio, 50:257
motor performance, Alzheimer's disease, 50:163
motor performance, electroencephalography, 50:163
motor performance, temporal lobes, 50:163
music perception, Alzheimer's disease, 50:163
music perception, electroencephalography, 50:163
myotonic dystrophy, basal ganglia, 50:93
myotonic dystrophy, frontal lobes, 50:93
myotonic dystrophy, positron emission tomography, 50:93

- Aging** continued
 positron emission tomography, basal ganglia, 50:93
 positron emission tomography, frontal lobes, 50:93
 positron emission tomography, myotonic dystrophy, 50:93
 regional cerebral blood flow, affective disorder, 50:233
 regional cerebral blood flow, unipolar depression, 50:233
 single photon emission computed tomography, affective disorder, 50:233
 single photon emission computed tomography, unipolar depression, 50:233
 spectral analysis, Alzheimer's disease, 50:151
 spectral analysis, dipole analysis, 50:151
 spectral analysis, electroencephalography, 50:151
 temporal lobes, Alzheimer's disease, 50:163
 temporal lobes, electroencephalography, 50:163
 temporal lobes, motor performance, 50:163
 unipolar depression, regional cerebral blood flow, 50:233
 unipolar depression, single photon emission computed tomography, 50:233
 ventricle-brain ratio, alcohol dependence, 50:257
 ventricle-brain ratio, cerebrospinal fluid volume, 50:257
 ventricle-brain ratio, computed tomography, 50:257
 ventricle-brain ratio, magnetic resonance imaging, 50:257
- Alcohol dependence**
 aging, cerebrospinal fluid volume, 50:257
 aging, computed tomography, 50:257
 aging, magnetic resonance imaging, 50:257
 aging, ventricle-brain ratio, 50:257
 benzodiazepine receptor, flumazenil, 50:1
 benzodiazepine receptor, magnetic resonance imaging, 50:1
 benzodiazepine receptor, positron emission tomography, 50:1
 cerebrospinal fluid volume, aging, 50:257
 cerebrospinal fluid volume, computed tomography, 50:257
 cerebrospinal fluid volume, magnetic resonance imaging, 50:257
 cerebrospinal fluid volume, ventricle-brain ratio, 50:257
 computed tomography, aging, 50:257
 computed tomography, cerebrospinal fluid volume, 50:257
- Alcohol dependence** continued
 computed tomography, image segmentation, 50:101
 computed tomography, Korsakoff syndrome, 50:101
 computed tomography, magnetic resonance imaging, 50:257
 computed tomography, thresholding methods, 50:101
 computed tomography, ventricle-brain ratio, 50:257
 flumazenil, benzodiazepine receptor, 50:1
 flumazenil, magnetic resonance imaging, 50:1
 flumazenil, positron emission tomography, 50:1
 image segmentation, computed tomography, 50:101
 image segmentation, Korsakoff syndrome, 50:101
 image segmentation, thresholding methods, 50:101
 Korsakoff syndrome, computed tomography, 50:101
 Korsakoff syndrome, image segmentation, 50:101
 Korsakoff syndrome, thresholding methods, 50:101
 magnetic resonance imaging, aging, 50:257
 magnetic resonance imaging, benzodiazepine receptor, 50:1
 magnetic resonance imaging, cerebrospinal fluid volume, 50:257
 magnetic resonance imaging, computed tomography, 50:257
 magnetic resonance imaging, flumazenil, 50:1
 magnetic resonance imaging, positron emission tomography, 50:1
 magnetic resonance imaging, ventricle-brain ratio, 50:1
 positron emission tomography, benzodiazepine receptor, 50:1
 positron emission tomography, flumazenil, 50:1
 positron emission tomography, magnetic resonance imaging, 50:1
 thresholding methods, computed tomography, 50:101
 thresholding methods, image segmentation, 50:101
 thresholding methods, Korsakoff syndrome, 50:101
 ventricle-brain ratio, aging, 50:257
 ventricle-brain ratio, cerebrospinal fluid volume, 50:257
 ventricle-brain ratio, computed tomography, 50:257
 ventricle-brain ratio, magnetic resonance imaging, 50:1, 50:257
- Alzheimer's disease**
 aging, dipole analysis, 50:151
 aging, electroencephalography, 50:151, 50:163

Alzheimer's disease continued
 aging, motor performance, 50:163
 aging, music perception, 50:163
 aging, spectral analysis, 50:151
 aging, temporal lobes, 50:163
 dipole analysis, aging, 50:151
 dipole analysis, electroencephalography, 50:151
 dipole analysis, spectral analysis, 50:151
 electroencephalography, aging, 50:151, 163
 electroencephalography, dipole analysis, 50:151
 electroencephalography, motor performance, 50:163
 electroencephalography, music perception, 50:163
 electroencephalography, spectral analysis, 50:151
 electroencephalography, temporal lobes, 50:163
 motor performance, aging, 50:163
 motor performance, electroencephalography, 50:163
 motor performance, temporal lobes, 50:163
 music perception, aging, 50:163
 music perception, electroencephalography, 50:163
 spectral analysis, aging, 50:151
 spectral analysis, dipole analysis, 50:151
 spectral analysis, electroencephalography, 50:151
 temporal lobes, aging, 50:163
 temporal lobes, electroencephalography, 50:163
 temporal lobes, motor performance, 50:163
Anxiety
 phobia, positron emission tomography, 50:15
 phobia, regional cerebral blood flow, 50:15
 positron emission tomography, phobia, 50:15
 regional cerebral blood flow, phobia, 50:15
Basal ganglia
 aging, frontal lobes, 50:93
 aging, myotonic dystrophy, 50:93
 aging, positron emission tomography, 50:93
 caudate nucleus, magnetic resonance imaging, 50:89
 caudate nucleus, obsessive-compulsive disorder, 50:89
 computed tomography, neurological soft signs, 50:143
 computed tomography, obsessive-compulsive disorder, 50:143
 computed tomography, ventricle-brain ratio, 50:143
 dopamine D₂ receptors, methamphetamine psychosis, 50:217

Basal ganglia continued
 dopamine D₂ receptors, methylspiperone, 50:217
 dopamine D₂ receptors, positron emission tomography, 50:217
 dopamine D₂ receptors, serotonin S₂ receptors, 50:217
 frontal lobes, aging, 50:93
 frontal lobes, myotonic dystrophy, 50:93
 frontal lobes, positron emission tomography, 50:93
 magnetic resonance imaging, caudate nucleus, 50:89
 magnetic resonance imaging, motor learning, 50:33
 magnetic resonance imaging, obsessive-compulsive disorder, 50:89
 magnetic resonance imaging, schizophrenia, 50:33
 magnetic resonance imaging, tardive dyskinesia, 50:33
 methamphetamine psychosis, dopamine D₂ receptors, 50:217
 methamphetamine psychosis, methylspiperone, 50:217
 methamphetamine psychosis, positron emission tomography, 50:217
 methamphetamine psychosis, serotonin S₂ receptors, 50:217
 methylspiperone, dopamine D₂ receptors, 50:217
 methylspiperone, methamphetamine psychosis, 50:217
 methylspiperone, positron emission tomography, 50:217
 methylspiperone, serotonin S₂ receptors, 50:217
 motor learning, magnetic resonance imaging, 50:33
 motor learning, schizophrenia, 50:33
 motor learning, tardive dyskinesia, 50:33
 myotonic dystrophy, aging, 50:93
 myotonic dystrophy, frontal lobes, 50:93
 myotonic dystrophy, positron emission tomography, 50:93
 neurological soft signs, computed tomography, 50:143
 neurological soft signs, obsessive-compulsive disorder, 50:143
 neurological soft signs, ventricle-brain ratio, 50:143
 obsessive-compulsive disorder, caudate nucleus, 50:89
 obsessive-compulsive disorder, computed tomography, 50:143

Basal ganglia continued

- obsessive-compulsive disorder, magnetic resonance imaging, 50:89
- obsessive-compulsive disorder, neurological soft signs, 50:143
- obsessive-compulsive disorder, ventricle-brain ratio, 50:143
- positron emission tomography, aging, 50:93
- positron emission tomography, dopamine D₂ receptors, 50:217
- positron emission tomography, frontal lobes, 50:93
- positron emission tomography, methamphetamine psychosis, 50:217
- positron emission tomography, methylspiperone, 50:217
- positron emission tomography, myotonic dystrophy, 50:93
- positron emission tomography, serotonin S₂ receptors, 50:217
- schizophrenia, magnetic resonance imaging, 50:33
- schizophrenia, motor learning, 50:33
- schizophrenia, tardive dyskinesia, 50:33
- serotonin S₂ receptors, dopamine D₂ receptors, 50:217
- serotonin S₂ receptors, methamphetamine psychosis, 50:217
- serotonin S₂ receptors, methylspiperone, 50:217
- serotonin S₂ receptors, positron emission tomography, 50:217
- tardive dyskinesia, magnetic resonance imaging, 50:33
- tardive dyskinesia, motor learning, 50:33
- tardive dyskinesia, schizophrenia, 50:33
- ventricle-brain ratio, computed tomography, 50:143
- ventricle-brain ratio, obsessive-compulsive disorder, 50:143
- ventricle-brain ratio, neurological soft signs, 50:143

Benzodiazepines

- alcohol dependence, flumazenil, 50:1
- alcohol dependence, magnetic resonance imaging, 50:1
- alcohol dependence, positron emission tomography, 50:1
- flumazenil, alcohol dependence, 50:1
- flumazenil, magnetic resonance imaging, 50:1
- flumazenil, positron emission tomography, 50:1
- magnetic resonance imaging, alcohol dependence, 50:1
- magnetic resonance imaging, flumazenil, 50:1

Benzodiazepines continued

- magnetic resonance imaging, positron emission tomography, 50:1
- positron emission tomography, alcohol dependence, 50:1
- positron emission tomography, flumazenil, 50:1
- positron emission tomography, magnetic resonance imaging, 50:1
- Cavum septum pellucidum**
- development, magnetic resonance imaging, 50:193
- development, schizophrenia, 50:193
- magnetic resonance imaging, development, 50:193
- magnetic resonance imaging, schizophrenia, 50:193
- schizophrenia, development, 50:193
- schizophrenia, magnetic resonance imaging, 50:193
- Cerebral blood flow.** See *Regional cerebral imaging, blood flow*.
- Cerebrospinal fluid volume**
- aging, alcohol dependence, 50:257
- aging, computed tomography, 50:257
- aging, magnetic resonance imaging, 50:257
- aging, ventricle-brain ratio, 50:257
- alcohol dependence, aging, 50:257
- alcohol dependence, computed tomography, 50:257
- alcohol dependence, magnetic resonance imaging, 50:257
- alcohol dependence, ventricle-brain ratio, 50:257
- computed tomography, aging, 50:257
- computed tomography, alcohol dependence, 50:257
- computed tomography, magnetic resonance 50:257
- computed tomography, ventricle-brain ratio, 50:257
- magnetic resonance imaging, aging, 50:257
- magnetic resonance imaging, alcohol dependence, 50:257
- magnetic resonance imaging, computed tomography, 50:257
- magnetic resonance imaging, ventricle-brain ratio, 50:257
- ventricle-brain ratio, aging, 50:257
- ventricle-brain ratio, alcohol dependence, 50:257
- ventricle-brain ratio, computed tomography, 50:257
- ventricle-brain ratio, magnetic resonance imaging, 50:257

- Clomipramine**
- clinical response prediction, 50:25
 - electroencephalography, 50:25
 - electroencephalography, clinical response prediction, 50:25
- Cognition**
- electroencephalography, nootropic, 50:275
 - electroencephalography, piracetam, 50:275
 - electroencephalography, topographic analysis, 50:275
 - nootropic, electroencephalography, 50:275
 - nootropic, piracetam, 50:275
 - nootropic, topographic analysis, 50:275
 - piracetam, electroencephalography, 50:275
 - piracetam, nootropic, 50:275
 - piracetam, topographic analysis, 50:275
 - topographic analysis, electroencephalography, 50:275
 - topographic analysis, nootropic, 50:275
 - topographic analysis, piracetam, 50:275
- Computed tomography**
- aging, alcohol dependence, 50:257
 - aging, cerebrospinal fluid volume, 50:257
 - aging, magnetic resonance imaging, 50:257
 - aging, ventricle-brain ratio, 50:257
 - alcohol dependence, aging, 50:257
 - alcohol dependence, cerebrospinal fluid volume, 50:257
 - alcohol dependence, image segmentation, 50:101
 - alcohol dependence, Korsakoff syndrome, 50:101
 - alcohol dependence, magnetic resonance imaging, 50:257
 - alcohol dependence, thresholding methods, 50:101
 - alcohol dependence, ventricle-brain ratio, 50:257
 - basal ganglia, neurological soft signs, 50:143
 - basal ganglia, obsessive-compulsive disorder, 50:143
 - basal ganglia, ventricle-brain ratio, 50:143
 - cerebrospinal fluid volume, aging, 50:257
 - cerebrospinal fluid volume, alcohol dependence, 50:257
 - cerebrospinal fluid volume, magnetic resonance imaging, 50:257
 - cerebrospinal fluid volume, ventricle-brain ratio, 50:257
 - head size, magnetic resonance imaging, 50:121
 - head size, ventricle-brain ratio, 50:121
 - image segmentation, alcohol dependence, 50:101
 - image segmentation, Korsakoff syndrome, 50:101
- Computed tomography** continued
- image segmentation, thresholding methods, 50:101
 - Korsakoff syndrome, alcohol dependence, 50:101
 - Korsakoff syndrome, image segmentation, 50:101
 - Korsakoff syndrome, thresholding methods, 50:101
 - magnetic resonance imaging, aging, 50:257
 - magnetic resonance imaging, alcohol dependence, 50:257
 - magnetic resonance imaging, cerebrospinal fluid volume, 50:257
 - magnetic resonance imaging, head size, 50:121
 - magnetic resonance imaging, ventricle-brain ratio, 50:121, 50:257
 - neurological soft signs, basal ganglia, 50:143
 - neurological soft signs, obsessive-compulsive disorder, 50:143
 - neurological soft signs, ventricle-brain ratio, 50:143
 - obsessive-compulsive disorder, basal ganglia, 50:143
 - obsessive-compulsive disorder, neurological soft signs, 50:143
 - obsessive-compulsive disorder, ventricle-brain ratio, 50:143
 - thresholding methods, alcohol dependence, 50:101
 - thresholding methods, image segmentation, 50:101
 - thresholding methods, Korsakoff syndrome, 50:101
 - ventricle-brain ratio, aging, 50:257
 - ventricle-brain ratio, alcohol dependence, 50:257
 - ventricle-brain ratio, basal ganglia, 50:143
 - ventricle-brain ratio, cerebrospinal fluid volume, 50:257
 - ventricle-brain ratio, head size, 50:121
 - ventricle-brain ratio, magnetic resonance imaging, 50:121, 50:257
 - ventricle-brain ratio, neurological soft signs, 50:143
 - ventricle-brain ratio, obsessive-compulsive disorder, 50:143
- Dementia.** See Alzheimer's disease.
- Depression.** See Affective disorder.
- Development**
- cavum septum pellucidum, magnetic resonance imaging, 50:193
 - cavum septum pellucidum, schizophrenia, 50:193

- Development** continued
 magnetic resonance imaging, cavum septum pellucidum, 50:193
 magnetic resonance imaging, schizophrenia, 50:193
 schizophrenia, cavum septum pellucidum, 50:193
 schizophrenia, magnetic resonance imaging, 50:193
- Dopamine**
 basal ganglia, methamphetamine psychosis, 50:217
 basal ganglia, methylspiperone, 50:217
 basal ganglia, positron emission tomography, 50:217
 basal ganglia, serotonin S₂ receptors, 50:217
 methamphetamine psychosis, basal ganglia, 50:217
 methamphetamine psychosis, methylspiperone, 50:217
 methamphetamine psychosis, positron emission tomography, 50:217
 methamphetamine psychosis, serotonin S₂ receptors, 50:217
 methylspiperone, basal ganglia, 50:217
 methylspiperone, methamphetamine psychosis, 50:217
 methylspiperone, positron emission tomography, 50:217
 methylspiperone, serotonin S₂ receptors, 50:217
 positron emission tomography, basal ganglia, 50:217
 positron emission tomography, methamphetamine psychosis, 50:217
 positron emission tomography, methylspiperone, 50:217
 positron emission tomography, serotonin S₂ receptors, 50:217
 serotonin S₂ receptors, basal ganglia, 50:217
 serotonin S₂ receptors, methamphetamine psychosis, 50:217
 serotonin S₂ receptors, methylspiperone, 50:217
 serotonin S₂ receptors, positron emission tomography, 50:217
- Electroencephalography**
 aging, Alzheimer's disease, 50:151, 50:163
 aging, dipole analysis, 50:151
 aging, motor performance, 50:163
 aging, music perception, 50:163
 aging, spectral analysis, 50:151
 aging, temporal lobes, 50:163
 Alzheimer's disease, aging, 50:151, 50:163
 Alzheimer's disease, dipole analysis, 50:151
- Electroencephalography** continued
 Alzheimer's disease, motor performance, 50:163
 Alzheimer's disease, music perception, 50:163
 Alzheimer's disease, spectral analysis, 50:151
 Alzheimer's disease, temporal lobes, 50:163
 clinical response prediction, fluoxetine, 50:25
 clinical response prediction, obsessive-compulsive disorder, 50:25
 clinical response prediction, serotonin reuptake inhibitors, 50:25
 cognition, nootropic, 50:275
 cognition, piracetam, 50:275
 cognition, topographic analysis, 50:275
 dipole analysis, aging, 50:151
 dipole analysis, Alzheimer's disease, 50:151
 dipole analysis, spectral analysis, 50:151
 fluoxetine, clinical response prediction, 50:25
 fluoxetine, obsessive-compulsive disorder, 50:25
 motor performance, aging, 50:163
 motor performance, Alzheimer's disease, 50:163
 motor performance, temporal lobes, 50:163
 music perception, aging, 50:163
 music perception, Alzheimer's disease, 50:163
 nootropic, cognition, 50:275
 nootropic, topographic analysis, 50:275
 obsessive-compulsive disorder, clinical response prediction, 50:25
 obsessive-compulsive disorder, fluoxetine, 50:25
 obsessive-compulsive disorder, serotonin reuptake inhibitors, 50:25
 piracetam, cognition, 50:275
 piracetam, topographic analysis, 50:275
 serotonin reuptake inhibitors, clinical response prediction, 50:25
 serotonin reuptake inhibitors, obsessive-compulsive disorder, 50:25
 space-oriented segmentation, topographic analysis, 50:275
 spectral analysis, aging, 50:151
 spectral analysis, Alzheimer's disease, 50:151
 spectral analysis, dipole analysis, 50:151
 temporal lobes, aging, 50:163
 temporal lobes, Alzheimer's disease, 50:163
 temporal lobes, motor performance, 50:163
 topographic analysis, cognition, 50:275
 topographic analysis, nootropic, 50:275
 topographic analysis, piracetam, 50:275
 topographic analysis, space-oriented segmentation, 50:275

Flumazenil

- alcohol dependence, benzodiazepine receptor, 50:1
- alcohol dependence, magnetic resonance imaging, 50:1
- alcohol dependence, positron emission tomography, 50:1
- benzodiazepine receptor, alcohol dependence, 50:1
- benzodiazepine receptor, magnetic resonance imaging, 50:1
- benzodiazepine receptor, positron emission tomography, 50:1
- magnetic resonance imaging, alcohol dependence, 50:1
- magnetic resonance imaging, benzodiazepine receptor, 50:1
- magnetic resonance imaging, positron emission tomography, 50:1
- positron emission tomography, alcohol dependence, 50:1
- positron emission tomography, benzodiazepine receptor, 50:1
- positron emission tomography, magnetic resonance imaging, 50:1

Fluoxetine

- clinical response prediction, electroencephalography, 50:25
- clinical response prediction, obsessive-compulsive disorder, 50:25
- electroencephalography, clinical response prediction, 50:25
- electroencephalography, obsessive-compulsive disorder, 50:25
- obsessive-compulsive disorder, clinical response prediction, 50:25
- obsessive-compulsive disorder, electroencephalography, 50:25

Fluvoxamine

- clinical response prediction, electroencephalography, 50:25
- electroencephalography, clinical response prediction, 50:25

Frontal lobes

- affective disorder, regional cerebral blood flow, 50:77
- affective disorder, single photon emission computed tomography, 50:77
- aging, basal ganglia, 50:93
- aging, myotonic dystrophy, 50:93
- aging, positron emission tomography, 50:93
- basal ganglia, aging, 50:93
- basal ganglia, myotonic dystrophy, 50:93
- basal ganglia, positron emission tomography, 50:93

Frontal lobes continued

- catatonia, iodoamphetamine, 50:203
- catatonia, parietal lobes, 50:203
- catatonia, regional cerebral blood flow, 50:203
- catatonia, schizophrenia, 50:203
- catatonia, single photon emission computed tomography, 50:203
- iodoamphetamine, catatonia, 50:203
- iodoamphetamine, parietal lobes, 50:203
- iodoamphetamine, regional cerebral blood flow, 50:203
- iodoamphetamine, schizophrenia, 50:203
- iodoamphetamine, single photon emission computed tomography, 50:203
- myotonic dystrophy, aging, 50:93
- myotonic dystrophy, basal ganglia, 50:93
- myotonic dystrophy, positron emission tomography, 50:93
- parietal lobes, catatonia, 50:203
- parietal lobes, iodoamphetamine, 50:203
- parietal lobes, regional cerebral blood flow, 50:203
- parietal lobes, schizophrenia, 50:203
- parietal lobes, single photon emission computed tomography, 50:203
- positron emission tomography, aging, 50:93
- positron emission tomography, basal ganglia, 50:93
- positron emission tomography, myotonic dystrophy, 50:93
- regional cerebral blood flow, affective disorder, 50:77
- regional cerebral blood flow, catatonia, 50:203
- regional cerebral blood flow, iodoamphetamine, 50:203
- regional cerebral blood flow, parietal lobes, 50:203
- regional cerebral blood flow, schizophrenia, 50:203
- regional cerebral blood flow, single photon emission computed tomography, 50:77
- regional cerebral blood flow, single photon emission computed tomography, 50:177
- regional cerebral blood flow, single photon emission computed tomography, 50:203
- regional cerebral blood flow, task difficulty, 50:177
- regional cerebral blood flow, unipolar depression, 50:77
- regional cerebral blood flow, Wisconsin Card Sorting Test, 50:177
- schizophrenia, catatonia, 50:203
- schizophrenia, iodoamphetamine, 50:203

Frontal lobes continued

- schizophrenia, parietal lobes, 50:203
- schizophrenia, regional cerebral blood flow, 50:203
- schizophrenia, single photon emission computed tomography, 50:203
- single photon emission computed tomography, affective disorder, 50:77
- single photon emission computed tomography, catatonia, 50:203
- single photon emission computed tomography, iodoamphetamine, 50:203
- single photon emission computed tomography, parietal lobes, 50:203
- single photon emission computed tomography, schizophrenia, 50:203
- single photon emission computed tomography, task difficulty, 50:177
- single photon emission computed tomography, unipolar depression, 50:77
- single photon emission computed tomography, Wisconsin Card Sorting Test, 50:177
- task difficulty, regional cerebral blood flow, 50:177
- task difficulty, single photon emission computed tomography, 50:177
- task difficulty, Wisconsin Card Sorting Test, 50:177
- unipolar depression, regional cerebral blood flow, 50:77
- unipolar depression, single photon emission computed tomography, 50:77
- Wisconsin Card Sorting Test, regional cerebral blood flow, 50:177
- Wisconsin Card Sorting Test, single photon emission computed tomography, 50:177
- Wisconsin Card Sorting Test, task difficulty, 50:177

Image reconstruction

- magnetic resonance imaging, region of interest, 50:57
- magnetic resonance imaging, single photon emission computed tomography, 50:57
- region of interest, magnetic resonance imaging, 50:57
- region of interest, single photon emission computed tomography, 50:57
- single photon emission computed tomography, magnetic resonance imaging, 50:57
- single photon emission computed tomography, region of interest, 50:57

Image segmentation

- alcohol dependence, computed tomography, 50:101

Image segmentation continued

- alcohol dependence, Korsakoff syndrome, 50:101
- alcohol dependence, thresholding methods, 50:101
- computed tomography, alcohol dependence, 50:101
- computed tomography, Korsakoff syndrome, 50:101
- computed tomography, thresholding methods, 50:101
- Korsakoff syndrome, alcohol dependence, 50:101
- Korsakoff syndrome, computed tomography, 50:101
- Korsakoff syndrome, thresholding methods, 50:101
- thresholding methods, alcohol dependence, 50:101
- thresholding methods, computed tomography, 50:101
- thresholding methods, Korsakoff syndrome, 50:101
- Iodoamphetamine**
- catatonia, frontal lobes, 50:203
- catatonia, parietal lobes, 50:203
- catatonia, regional cerebral blood flow, 50:203
- catatonia, schizophrenia, 50:203
- catatonia, single photon emission computed tomography, 50:203
- frontal lobes, catatonia, 50:203
- frontal lobes, parietal lobes, 50:203
- frontal lobes, regional cerebral blood flow, 50:203
- frontal lobes, schizophrenia, 50:203
- frontal lobes, single photon emission computed tomography, 50:203
- parietal lobes, catatonia, 50:203
- parietal lobes, frontal lobes, 50:203
- parietal lobes, regional cerebral blood flow, 50:203
- parietal lobes, schizophrenia, 50:203
- parietal lobes, single photon emission computed tomography, 50:203
- regional cerebral blood flow, catatonia, 50:203
- regional cerebral blood flow, frontal lobes, 50:203
- regional cerebral blood flow, parietal lobes, 50:203
- regional cerebral blood flow, schizophrenia, 50:203
- schizophrenia, catatonia, 50:203
- schizophrenia, frontal lobes, 50:203

- Iodoamphetamine** continued
- schizophrenia, parietal lobes, 50:203
 - schizophrenia, regional cerebral blood flow, 50:203
 - schizophrenia, single photon emission computed tomography, 50:203
 - single photon emission computed tomography, catatonia, 50:203
 - single photon emission computed tomography, frontal lobes, 50:203
 - single photon emission computed tomography, parietal lobes, 50:203
 - single photon emission computed tomography, schizophrenia, 50:203
- Korsakoff syndrome**
- alcohol dependence, computed tomography, 50:101
 - alcohol dependence, image segmentation, 50:101
 - alcohol dependence, thresholding methods, 50:101
 - computed tomography, alcohol dependence, 50:101
 - computed tomography, image segmentation, 50:101
 - computed tomography, thresholding methods, 50:101
 - image segmentation, alcohol dependence, 50:101
 - image segmentation, computed tomography, 50:101
 - image segmentation, thresholding methods, 50:101
 - thresholding methods, alcohol dependence, 50:101
 - thresholding methods, computed tomography, 50:101
 - thresholding methods, image segmentation, 50:101
- Lithium**
- magnetic resonance spectroscopy, pharmacokinetics, 50:67
 - pharmacokinetics, magnetic resonance spectroscopy, 50:67
- Magnetic resonance imaging**
- aging, alcohol dependence, 50:257
 - aging, cerebrospinal fluid volume, 50:257
 - aging, computed tomography, 50:257
 - aging, ventricle-brain ratio, 50:257
 - alcohol dependence, aging, 50:257
 - alcohol dependence, benzodiazepine receptor, 50:1
 - alcohol dependence, cerebrospinal fluid volume, 50:257
- Magnetic resonance imaging** continued
- alcohol dependence, computed tomography, 50:257
 - alcohol dependence, flumazenil, 50:1
 - alcohol dependence, positron emission tomography, 50:1
 - alcohol dependence, ventricle-brain ratio, 50:1, 50:257
 - basal ganglia, motor learning, 50:33
 - basal ganglia, obsessive-compulsive disorder, 50:89
 - basal ganglia, schizophrenia, 50:33
 - basal ganglia, tardive dyskinesia, 50:33
 - benzodiazepine receptor, alcohol dependence, 50:1
 - benzodiazepine receptor, flumazenil, 50:1
 - benzodiazepine receptor, positron emission tomography, 50:1
 - caudate nucleus, obsessive-compulsive disorder, 50:89
 - cavum septum pellucidum, development, 50:193
 - cavum septum pellucidum, schizophrenia, 50:193
 - cerebrospinal fluid volume, aging, 50:257
 - cerebrospinal fluid volume, alcohol dependence, 50:257
 - cerebrospinal fluid volume, computed tomography, 50:257
 - cerebrospinal fluid volume, ventricle-brain ratio, 50:257
 - computed tomography, aging, 50:257
 - computed tomography, alcohol dependence, 50:257
 - computed tomography, cerebrospinal fluid volume, 50:257
 - computed tomography, head size, 50:121
 - computed tomography, ventricle-brain ratio, 50:121, 50:257
 - development, cavum septum pellucidum, 50:193
 - development, schizophrenia, 50:193
 - flumazenil, alcohol dependence, 50:1
 - flumazenil, benzodiazepine receptor, 50:1
 - flumazenil, positron emission tomography, 50:1
 - head size, computed tomography, 50:121
 - head size correction, reliability, 50:203
 - head size, schizophrenia, 50:121
 - head size, ventricle-brain ratio, 50:121
 - image registration, region of interest, 50:57
 - image registration, single photon emission computed tomography, 50:57
 - memory, schizophrenia, 50:45
 - memory, temporal lobe area, 50:45

Magnetic resonance imaging continued
 motor learning, basal ganglia, 50:33
 motor learning, schizophrenia, 50:33
 motor learning, tardive dyskinesia, 50:33
 obsessive-compulsive disorder, basal ganglia,
 50:89
 obsessive-compulsive disorder, caudate
 nucleus, 50:89
 positron emission tomography, alcohol
 dependence, 50:1
 positron emission tomography,
 benzodiazepine receptor, 50:1
 positron emission tomography, flumazenil,
 50:1
 region of interest, image registration, 50:57
 region of interest, single photon emission
 computed tomography, 50:57
 reliability, head size correction, 50:203
 schizophrenia, basal ganglia, 50:33
 schizophrenia, cavum septum pellucidum,
 50:193
 schizophrenia, development, 50:193
 schizophrenia, head size, 50:121
 schizophrenia, memory, 50:45
 schizophrenia, motor learning, 50:33
 schizophrenia, tardive dyskinesia, 50:33
 schizophrenia, temporal lobe area, 50:45
 single photon emission computed tomography,
 image registration, 50:57
 single photon emission computed tomography,
 region of interest, 50:57
 tardive dyskinesia, basal ganglia, 50:33
 tardive dyskinesia, motor learning, 50:33
 tardive dyskinesia, schizophrenia, 50:33
 temporal lobe area, memory, 50:45
 temporal lobe area, schizophrenia, 50:45
 ventricle-brain ratio, aging, 50:257
 ventricle-brain ratio, alcohol dependence,
 50:1, 50:257
 ventricle-brain ratio, cerebrospinal fluid
 volume, 50:257
 ventricle-brain ratio, computed tomography,
 50:121, 50:257
 ventricle-brain ratio, head size, 50:121
Magnetic resonance spectroscopy
 lithium, pharmacokinetics, 50:67
 pharmacokinetics, lithium, 50:67
Memory
 magnetic resonance imaging, schizophrenia,
 50:45
 magnetic resonance imaging, temporal lobe
 area, 50:45
 schizophrenia, magnetic resonance imaging,
 50:45
 schizophrenia, temporal lobe area, 50:45

Magnetic resonance spectroscopy continued
 temporal lobe area, magnetic resonance
 imaging, 50:45
 temporal lobe area, schizophrenia, 50:45
Methamphetamine
 basal ganglia, dopamine D₂ receptors, 50:217
 basal ganglia, methylspiperone, 50:217
 basal ganglia, positron emission tomography,
 50:217
 basal ganglia, serotonin S₂ receptors, 50:217
 dopamine D₂ receptors, basal ganglia, 50:217
 dopamine D₂ receptors, methylspiperone,
 50:217
 dopamine D₂ receptors, positron emission
 tomography, 50:217
 dopamine D₂ receptors, serotonin S₂
 receptors, 50:217
 methylspiperone, basal ganglia, 50:217
 methylspiperone, dopamine D₂ receptors,
 50:217
 methylspiperone, positron emission
 tomography, 50:217
 methylspiperone, serotonin S₂ receptors, 50:217
 positron emission tomography, basal ganglia,
 50:217
 positron emission tomography, dopamine D₂
 receptors, 50:217
 positron emission tomography,
 methylspiperone, 50:217
 positron emission tomography, serotonin S₂
 receptors, 50:217
 serotonin S₂ receptors, basal ganglia, 50:217
 serotonin S₂ receptors, dopamine D₂
 receptors, 50:217
 serotonin S₂ receptors, methylspiperone,
 50:217
 serotonin S₂ receptors, positron emission
 tomography, 50:217
Methylspiperone
 basal ganglia, dopamine D₂ receptors, 50:217
 basal ganglia, methamphetamine psychosis,
 50:217
 basal ganglia, positron emission tomography,
 50:217
 basal ganglia, serotonin S₂ receptors, 50:217
 dopamine D₂ receptors, basal ganglia, 50:217
 dopamine D₂ receptors, methamphetamine
 psychosis, 50:217
 dopamine D₂ receptors, positron emission
 tomography, 50:217
 dopamine D₂ receptors, serotonin S₂
 receptors, 50:217
 methamphetamine psychosis, basal ganglia, 50:217
 methamphetamine psychosis, dopamine D₂
 receptors, 50:217

Methylspiperone continued

- methamphetamine psychosis, positron emission tomography, 50:217
- methamphetamine psychosis, serotonin S₂ receptors, 50:217
- positron emission tomography, basal ganglia, 50:217
- positron emission tomography, dopamine D₂ receptors, 50:217
- positron emission tomography, methamphetamine psychosis, 50:217
- positron emission tomography, serotonin S₂ receptors, 50:217
- serotonin S₂ receptors, basal ganglia, 50:217
- serotonin S₂ receptors, dopamine D₂ receptors, 50:217
- serotonin S₂ receptors, methamphetamine psychosis, 50:217
- serotonin S₂ receptors, positron emission tomography, 50:217

Motor performance

- aging, Alzheimer's disease, 50:163
- aging, electroencephalography, 50:163
- aging, temporal lobes, 50:163
- Alzheimer's disease, aging, 50:163
- Alzheimer's disease, electroencephalography, 50:163
- Alzheimer's disease, temporal lobes, 50:163
- electroencephalography, aging, 50:163
- electroencephalography, Alzheimer's disease, 50:163
- electroencephalography, temporal lobes, 50:163
- temporal lobes, aging, 50:163
- temporal lobes, Alzheimer's disease, 50:163
- temporal lobes, electroencephalography, 50:163

Myotonic dystrophy

- aging, basal ganglia, 50:93
- aging, frontal lobes, 50:93
- aging, positron emission tomography, 50:93
- basal ganglia, aging, 50:93
- basal ganglia, frontal lobes, 50:93
- basal ganglia, positron emission tomography, 50:93
- frontal lobes, aging, 50:93
- frontal lobes, basal ganglia, 50:93
- frontal lobes, positron emission tomography, 50:93
- positron emission tomography, aging, 50:93
- positron emission tomography, basal ganglia, 50:93
- positron emission tomography, frontal lobes, 50:93

Neurological soft signs

- basal ganglia, computed tomography, 50:143

Neurological soft signs continued

- basal ganglia, obsessive-compulsive disorder, 50:143
- basal ganglia, ventricle-brain ratio, 50:143
- computed tomography, basal ganglia, 50:143
- computed tomography, obsessive-compulsive disorder, 50:143
- computed tomography, ventricle-brain ratio, 50:143
- obsessive-compulsive disorder, basal ganglia, 50:143
- obsessive-compulsive disorder, computed tomography, 50:143
- obsessive-compulsive disorder, ventricle-brain ratio, 50:143
- ventricle-brain ratio, basal ganglia, 50:143
- ventricle-brain ratio, obsessive-compulsive disorder, 50:143

Nootropics

- cognition, electroencephalography, 50:275
- cognition, piracetam, 50:275
- cognition, topographic analysis, 50:275
- electroencephalography, cognition, 50:275
- electroencephalography, piracetam, 50:275
- electroencephalography, topographic analysis, 50:275
- piracetam, cognition, 50:275
- piracetam, electroencephalography, 50:275
- piracetam, topographic analysis, 50:275
- topographic analysis, cognition, 50:275
- topographic analysis, electroencephalography, 50:275
- topographic analysis, piracetam, 50:275

Obsessive-compulsive disorder

- basal ganglia, computed tomography, 50:143
- basal ganglia, magnetic resonance imaging, 50:89
- basal ganglia, neurological soft signs, 50:143
- basal ganglia, ventricle-brain ratio, 50:143
- caudate nucleus, magnetic resonance imaging, 50:89
- clinical response prediction, electroencephalography, 50:25
- clinical response prediction, fluoxetine, 50:25
- clinical response prediction, serotonin reuptake inhibitors, 50:25
- computed tomography, basal ganglia, 50:143
- computed tomography, neurological soft signs, 50:143
- computed tomography, ventricle-brain ratio, 50:143
- electroencephalography, clinical response prediction, 50:25
- electroencephalography, fluoxetine, 50:25

- Obsessive-compulsive disorder** continued
 electroencephalography, serotonin reuptake inhibitors, 50:25
 fluoxetine, clinical response prediction, 50:25
 fluoxetine, electroencephalography, 50:25
 magnetic resonance imaging, basal ganglia, 50:89
 magnetic resonance imaging, caudate nucleus, 50:89
 neurological soft signs, basal ganglia, 50:143
 neurological soft signs, computed tomography, 50:143
 neurological soft signs, ventricle-brain ratio, 50:143
 serotonin reuptake inhibitors, clinical response prediction, 50:25
 serotonin reuptake inhibitors, electroencephalography, 50:25
 ventricle-brain ratio, basal ganglia, 50:143
 ventricle-brain ratio, neurological soft signs, 50:143
- Parietal lobes**
 catatonia, frontal lobes, 50:203
 catatonia, iodoamphetamine, 50:203
 catatonia, regional cerebral blood flow, 50:203
 catatonia, schizophrenia, 50:203
 catatonia, single photon emission computed tomography, 50:203
 frontal lobes, catatonia, 50:203
 frontal lobes, iodoamphetamine, 50:203
 frontal lobes, regional cerebral blood flow, 50:203
 frontal lobes, schizophrenia, 50:203
 frontal lobes, single photon emission computed tomography, 50:203
 iodoamphetamine, catatonia, 50:203
 iodoamphetamine, frontal lobes, 50:203
 iodoamphetamine, regional cerebral blood flow, 50:203
 iodoamphetamine, schizophrenia, 50:203
 iodoamphetamine, single photon emission computed tomography, 50:203
 regional cerebral blood flow, catatonia, 50:203
 regional cerebral blood flow, frontal lobes, 50:203
 regional cerebral blood flow, iodoamphetamine, 50:203
 regional cerebral blood flow, schizophrenia, 50:203
 schizophrenia, catatonia, 50:203
 schizophrenia, frontal lobes, 50:203
 schizophrenia, iodoamphetamine, 50:203

- Parietal lobes** continued
 schizophrenia, regional cerebral blood flow, 50:203
 schizophrenia, single photon emission computed tomography, 50:203
 single photon emission computed tomography, catatonia, 50:203
 single photon emission computed tomography, frontal lobes, 50:203
 single photon emission computed tomography, iodoamphetamine, 50:203
 single photon emission computed tomography, schizophrenia, 50:203
- Pharmacokinetics**
 lithium, magnetic resonance spectroscopy, 50:67
 magnetic resonance spectroscopy, lithium, 50:67
- Phobia**
 anxiety, positron emission tomography, 50:15
 anxiety, regional cerebral blood flow, 50:15
 positron emission tomography, anxiety, 50:15
 positron emission tomography, regional cerebral blood flow, 50:15
 positron emission tomography, snake anxiety, 50:15
 regional cerebral blood flow, anxiety, 50:15
 regional cerebral blood flow, positron emission tomography, 50:15
 snake anxiety, positron emission tomography, 50:15
- Piracetam**
 cognition, electroencephalography, 50:275
 cognition, topographic analysis, 50:275
 electroencephalography, cognition, 50:275
 electroencephalography, topographic analysis, 50:275
 topographic analysis, cognition, 50:275
 topographic analysis, electroencephalography, 50:275
- Positron emission tomography**
 aging, basal ganglia, 50:93
 aging, frontal lobes, 50:93
 aging, myotonic dystrophy, 50:93
 alcohol dependence, benzodiazepine receptor, 50:1
 alcohol dependence, flumazenil, 50:1
 alcohol dependence, magnetic resonance imaging, 50:1
 anxiety, phobia, 50:15
 anxiety, regional cerebral blood flow, 50:15
 basal ganglia, aging, 50:93
 basal ganglia, dopamine D₂ receptor, 50:217
 basal ganglia, frontal lobes, 50:93

- Positron emission tomography** continued
basal ganglia, methamphetamine psychosis, 50:217
basal ganglia, methylspiperone, 50:217
basal ganglia, myotonic dystrophy, 50:93
basal ganglia, serotonin S₂ receptors, 50:217
benzodiazepine receptor, alcohol dependence, 50:1
benzodiazepine receptor, flumazenil, 50:1
benzodiazepine receptor, magnetic resonance imaging, 50:1
dopamine D₂ receptors, basal ganglia, 50:217
dopamine D₂ receptors, methamphetamine psychosis, 50:217
dopamine D₂ receptors, methylspiperone, 50:217
dopamine D₂ receptors, serotonin S₂ receptors, 50:217
flumazenil, alcohol dependence, 50:1
flumazenil, benzodiazepine receptor, 50:1
flumazenil, magnetic resonance imaging, 50:1
frontal lobes, aging, 50:93
frontal lobes, basal ganglia, 50:93
frontal lobes, myotonic dystrophy, 50:93
magnetic resonance imaging, alcohol dependence, 50:1
magnetic resonance imaging, benzodiazepine receptor, 50:1
magnetic resonance imaging, flumazenil, 50:1
methamphetamine psychosis, basal ganglia, 50:217
methamphetamine psychosis, dopamine D₂ receptors, 50:217
methamphetamine psychosis, methylspiperone, 50:217
methamphetamine psychosis, serotonin S₂ receptors, 50:217
methylspiperone, basal ganglia, 50:217
methylspiperone, dopamine D₂ receptors, 50:217
methylspiperone, methamphetamine psychosis, 50:217
methylspiperone, serotonin S₂ receptors, 50:217
myotonic dystrophy, aging, 50:93
myotonic dystrophy, basal ganglia, 50:93
myotonic dystrophy, frontal lobes, 50:93
phobia, anxiety, 50:15
phobia, regional cerebral blood flow, 50:15
regional cerebral blood flow, anxiety, 50:15
regional cerebral blood flow, phobia, 50:15
serotonin S₂ receptors, basal ganglia, 50:217
serotonin S₂ receptors, dopamine D₂ receptors, 50:217
- Positron emission tomography** continued
serotonin S₂ receptors, methamphetamine psychosis, 50:217
serotonin S₂ receptors, methylspiperone, 50:217
Pursuit rotor task
motor learning, schizophrenia, 50:33
schizophrenia, motor learning, 50:33
Regional cerebral blood flow
affective disorder, aging, 50:233
affective disorder, frontal lobes, 50:77
affective disorder, single photon emission computed tomography, 50:233
aging, affective disorder, 50:233
aging, single photon emission computed tomography, 50:233
aging, unipolar depression, 50:233
anxiety, positron emission tomography, 50:15
catatonia, frontal lobes, 50:203
catatonia, iodoamphetamine, 50:203
catatonia, parietal lobes, 50:203
catatonia, schizophrenia, 50:203
catatonia, single photon emission computed tomography, 50:203
frontal lobes, affective disorder, 50:77
frontal lobes, catatonia, 50:203
frontal lobes, iodoamphetamine, 50:203
frontal lobes, parietal lobes, 50:203
frontal lobes, schizophrenia, 50:203
frontal lobes, single photon emission computed tomography, 50:77
frontal lobes, task difficulty, 50:177
frontal lobes, unipolar depression, 50:77
frontal lobes, Wisconsin Card Sorting Test, 50:177
iodoamphetamine, catatonia, 50:203
iodoamphetamine, frontal lobes, 50:203
iodoamphetamine, parietal lobes, 50:203
iodoamphetamine, schizophrenia, 50:203
iodoamphetamine, single photon emission computed tomography, 50:203
parietal lobes, catatonia, 50:203
parietal lobes, frontal lobes, 50:203
parietal lobes, iodoamphetamine, 50:203
parietal lobes, schizophrenia, 50:203
parietal lobes, single photon emission computed tomography, 50:203
phobia, positron emission tomography, 50:15
positron emission tomography, anxiety, 50:15
positron emission tomography, phobia, 50:15
schizophrenia, catatonia, 50:203
schizophrenia, frontal lobes, 50:203
schizophrenia, iodoamphetamine, 50:203

Regional cerebral blood flow

- schizophrenia, parietal lobes, 50:203
 - schizophrenia, single photon emission computed tomography, 50:203
 - single photon emission computed tomography, affective disorder, 50:77, 50:233
 - single photon emission computed tomography, aging, 50:233
 - single photon emission computed tomography, catatonia, 50:233
 - single photon emission computed tomography, frontal lobes, 50:77, 50:177, 50:233
 - single photon emission computed tomography, iodoamphetamine, 50:233
 - single photon emission computed tomography, parietal lobes, 50:203
 - single photon emission computed tomography, schizophrenia, 50:203
 - single photon emission computed tomography, task difficulty, 50:177
 - single photon emission computed tomography, unipolar depression, 50:77, 50:233
 - single photon emission computed tomography, Wisconsin Card Sorting Test, 50:177
 - task difficulty, frontal lobes, 50:177
 - task difficulty, single photon emission computed tomography, 50:177
 - task difficulty, Wisconsin Card Sorting Test, 50:177
 - unipolar depression, aging, 50:233
 - unipolar depression, frontal lobes, 50:77
 - unipolar depression, single photon emission computed tomography, 50:77, 50:233
 - Wisconsin Card Sorting Test, frontal lobes, 50:177
 - Wisconsin Card Sorting Test, single photon emission computed tomography, 50:177
 - Wisconsin Card Sorting Test, task difficulty, 50:177
- Schizophrenia**
- basal ganglia, magnetic resonance imaging, 50:33
 - basal ganglia, motor learning, 50:33
 - basal ganglia, tardive dyskinesia, 50:33
 - catatonia, frontal lobes, 50:203
 - catatonia, iodoamphetamine, 50:203
 - catatonia, parietal lobes, 50:203
 - catatonia, regional cerebral blood flow, 50:203
 - catatonia, single photon emission computed tomography, 50:203
 - cavum septum pellucidum, development, 50:193
 - cavum septum pellucidum, magnetic resonance imaging, 50:193

Schizophrenia continued

- development, cavum septum pellucidum, 50:193
- development, magnetic resonance imaging, 50:193
- frontal lobes, catatonia, 50:203
- frontal lobes, iodoamphetamine, 50:203
- frontal lobes, parietal lobes, 50:203
- frontal lobes, regional cerebral blood flow, 50:203
- frontal lobes, single photon emission computed tomography, 50:203
- head size, magnetic resonance imaging, 50:121
- iodoamphetamine, catatonia, 50:203
- iodoamphetamine, frontal lobes, 50:203
- iodoamphetamine, parietal lobes, 50:203
- iodoamphetamine, regional cerebral blood flow, 50:203
- iodoamphetamine, single photon emission computed tomography, 50:203
- magnetic resonance imaging, basal ganglia, 50:33
- magnetic resonance imaging, cavum septum pellucidum, 50:193
- magnetic resonance imaging, development, 50:193
- magnetic resonance imaging, head size, 50:121
- magnetic resonance imaging, memory, 50:45
- magnetic resonance imaging, motor learning, 50:33
- magnetic resonance imaging, tardive dyskinesia, 50:33
- magnetic resonance imaging, temporal lobe area, 50:45
- memory, magnetic resonance imaging, 50:45
- memory, temporal lobe area, 50:45
- motor learning, basal ganglia, 50:33
- motor learning, magnetic resonance imaging, 50:33
- motor learning, tardive dyskinesia, 50:33
- parietal lobes, catatonia, 50:203
- parietal lobes, frontal lobes, 50:203
- parietal lobes, iodoamphetamine, 50:203
- parietal lobes, regional cerebral blood flow, 50:203
- parietal lobes, single photon emission computed tomography, 50:203
- regional cerebral blood flow, catatonia, 50:203
- regional cerebral blood flow, frontal lobes, 50:203
- regional cerebral blood flow, iodoamphetamine, 50:203

Schizophrenia continued

- regional cerebral blood flow, parietal lobes, 50:203
 - single photon emission computed tomography, catatonia, 50:203
 - single photon emission computed tomography, frontal lobes, 50:203
 - single photon emission computed tomography, iodoamphetamine, 50:203
 - single photon emission computed tomography, parietal lobes, 50:203
 - tardive dyskinesia, basal ganglia, 50:33
 - tardive dyskinesia, magnetic resonance imaging, 50:33
 - tardive dyskinesia, motor learning, 50:33
 - temporal lobe area, magnetic resonance imaging, 50:45
 - temporal lobe area, memory, 50:45
- Serotonin**
- basal ganglia, dopamine D₂ receptors, 50:217
 - basal ganglia, methamphetamine psychosis, 50:217
 - basal ganglia, methylspiperone, 50:217
 - basal ganglia, positron emission tomography, 50:217
 - clinical response prediction, electroencephalography, 50:25
 - clinical response prediction, obsessive-compulsive disorder, 50:25
 - dopamine D₂ receptors, basal ganglia, 50:217
 - dopamine D₂ receptors, methamphetamine psychosis, 50:217
 - dopamine D₂ receptors, methylspiperone, 50:217
 - dopamine D₂ receptors, positron emission tomography, 50:217
 - electroencephalography, clinical response prediction, 50:25
 - electroencephalography, obsessive-compulsive disorder, 50:25
 - methamphetamine psychosis, basal ganglia, 50:217
 - methamphetamine psychosis, dopamine D₂ receptors, 50:217
 - methamphetamine psychosis, methylspiperone, 50:217
 - methamphetamine psychosis, positron emission tomography, 50:217
 - methylspiperone, basal ganglia, 50:217
 - methylspiperone, dopamine D₂ receptors, 50:217
 - methylspiperone, methamphetamine psychosis, 50:217
 - methylspiperone, positron emission tomography, 50:217

Serotonin continued

- obsessive-compulsive disorder, clinical response prediction, 50:25
 - obsessive-compulsive disorder, electroencephalography, 50:25
 - positron emission tomography, basal ganglia, 50:217
 - positron emission tomography, dopamine D₂ receptors, 50:217
 - positron emission tomography, methamphetamine psychosis, 50:217
 - positron emission tomography, methylspiperone, 50:217
- Single photon emission computed tomography**
- affective disorder, aging, 50:233
 - affective disorder, frontal lobes, 50:77
 - affective disorder, regional cerebral blood flow, 50:77, 50:233
 - aging, affective disorder, 50:233
 - aging, regional cerebral blood flow, 50:233
 - aging, unipolar depression, 50:233
 - catatonia, frontal lobes, 50:203
 - catatonia, iodoamphetamine, 50:203
 - catatonia, parietal lobes, 50:203
 - catatonia, regional cerebral blood flow, 50:203
 - catatonia, schizophrenia, 50:203
 - frontal lobes, affective disorder, 50:77
 - frontal lobes, catatonia, 50:203
 - frontal lobes, iodoamphetamine, 50:203
 - frontal lobes, parietal lobes, 50:203
 - frontal lobes, regional cerebral blood flow, 50:77, 50:177, 50:203
 - frontal lobes, schizophrenia, 50:203
 - frontal lobes, task difficulty, 50:177
 - frontal lobes, unipolar depression, 50:77
 - frontal lobes, Wisconsin Card Sorting Test, 50:177
 - image registration, magnetic resonance imaging, 50:57
 - image registration, region of interest, 50:57
 - iodoamphetamine, catatonia, 50:203
 - iodoamphetamine, frontal lobes, 50:203
 - iodoamphetamine, parietal lobes, 50:203
 - iodoamphetamine, regional cerebral blood flow, 50:203
 - iodoamphetamine, schizophrenia, 50:203
 - magnetic resonance imaging, image registration, 50:57
 - magnetic resonance imaging, region of interest, 50:57
 - parietal lobes, catatonia, 50:203
 - parietal lobes, frontal lobes, 50:203
 - parietal lobes, iodoamphetamine, 50:203

Single photon emission computed tomography continued
 parietal lobes, regional cerebral blood flow, 50:203
 parietal lobes, schizophrenia, 50:203
 region of interest, image registration, 50:57
 region of interest, magnetic resonance imaging, 50:57
 regional cerebral blood flow, affective disorder, 50:77, 50:233
 regional cerebral blood flow, aging, 50:233
 regional cerebral blood flow, catatonia, 50:203
 regional cerebral blood flow, frontal lobes, 50:77, 50:177, 50:203
 regional cerebral blood flow, iodoamphetamine, 50:203
 regional cerebral blood flow, parietal lobes, 50:203
 regional cerebral blood flow, schizophrenia, 50:203
 regional cerebral blood flow, task difficulty, 50:177
 regional cerebral blood flow, unipolar depression, 50:77, 50:233
 regional cerebral blood flow, Wisconsin Card Sorting Test, 50:177
 schizophrenia, catatonia, 50:203
 schizophrenia, frontal lobes, 50:203
 schizophrenia, iodoamphetamine, 50:203
 schizophrenia, parietal lobes, 50:203
 schizophrenia, regional cerebral blood flow, 50:203
 task difficulty, frontal lobes, 50:177
 task difficulty, regional cerebral blood flow, 50:177
 task difficulty, Wisconsin Card Sorting Test, 50:177
 unipolar depression, affective disorder, 50:77, 50:233
 unipolar depression, aging, 50:233
 unipolar depression, frontal lobes, 50:77
 unipolar depression, regional cerebral blood flow, 50:77, 50:233
 Wisconsin Card Sorting Test, frontal lobes, 50:177
 Wisconsin Card Sorting Test, regional cerebral blood flow, 50:177
 Wisconsin Card Sorting Test, task difficulty, 50:177
Tardive dyskinesia
 basal ganglia, magnetic resonance imaging, 50:33
 basal ganglia, motor learning, 50:33
 basal ganglia, schizophrenia, 50:33

Tardive dyskinesia continued
 magnetic resonance imaging, basal ganglia, 50:33
 magnetic resonance imaging, motor learning, 50:33
 magnetic resonance imaging, schizophrenia, 50:33
 motor learning, basal ganglia, 50:33
 motor learning, magnetic resonance imaging, 50:33
 motor learning, schizophrenia, 50:33
 schizophrenia, basal ganglia, 50:33
 schizophrenia, magnetic resonance imaging, 50:33
 schizophrenia, motor learning, 50:33
Temporal lobes
 aging, Alzheimer's disease, 50:163
 aging, electroencephalography, 50:163
 aging, motor performance, 50:163
 Alzheimer's disease, aging, 50:163
 Alzheimer's disease, electroencephalography, 50:163
 Alzheimer's disease, motor performance, 50:163
 electroencephalography, aging, 50:163
 electroencephalography, Alzheimer's disease, 50:163
 electroencephalography, motor performance, 50:163
 magnetic resonance imaging, memory, 50:45
 magnetic resonance imaging, schizophrenia, 50:45
 memory, magnetic resonance imaging, 50:45
 memory, schizophrenia, 50:45
 motor performance, aging, 50:163
 motor performance, Alzheimer's disease, 50:163
 motor performance, electroencephalography, 50:163
 schizophrenia, magnetic resonance imaging, 50:45
 schizophrenia, memory, 50:45
Ventricle-brain ratio
 aging, alcohol dependence, 50:257
 aging, cerebrospinal fluid volume, 50:257
 aging, computed tomography, 50:257
 aging, magnetic resonance imaging, 50:257
 alcohol dependence, aging, 50:257
 alcohol dependence, cerebrospinal fluid volume, 50:257
 alcohol dependence, computed tomography, 50:257
 alcohol dependence, magnetic resonance imaging, 50:1, 50:257
 basal ganglia, computed tomography, 50:143

Ventrie-brain ratio continued

basal ganglia, neurological soft signs, 50:143
 basal ganglia, obsessive-compulsive disorder, 50:143
 cerebrospinal fluid volume, aging, 50:257
 cerebrospinal fluid volume, alcohol dependence, 50:257
 cerebrospinal fluid volume, computed tomography, 50:257
 cerebrospinal fluid volume, magnetic resonance imaging, 50:257
 computed tomography, aging, 50:257
 computed tomography, alcohol dependence, 50:257
 computed tomography, basal ganglia, 50:143
 computed tomography, cerebrospinal fluid volume, 50:257
 computed tomography, head size, 50:121
 computed tomography, magnetic resonance imaging, 50:121, 50:257
 computed tomography, neurological soft signs, 50:143
 computed tomography, obsessive-compulsive disorder, 50:143
 head size, computed tomography, 50:121
 head size, magnetic resonance imaging, 50:121
 magnetic resonance imaging, aging, 50:257
 magnetic resonance imaging, alcohol dependence, 50:1, 50:257
 magnetic resonance imaging, cerebrospinal fluid volume, 50:257
 magnetic resonance imaging, computed tomography, 50:121, 50:257
 magnetic resonance imaging, head size, 50:121
 magnetic resonance imaging, schizophrenia, 50:45
 magnetic resonance imaging, Wechsler Memory Scale, 50:45

Ventrie-brain ratio continued

neurological soft signs, basal ganglia, 50:143
 neurological soft signs, computed tomography, 50:143
 neurological soft signs, obsessive-compulsive disorder, 50:143
 obsessive-compulsive disorder, basal ganglia, 50:143
 obsessive-compulsive disorder, computed tomography, 50:143
 obsessive-compulsive disorder, neurological soft signs, 50:143
 schizophrenia, magnetic resonance imaging, 50:45
 schizophrenia, Wechsler Memory Scale, 50:45
 Wechsler Memory Scale, magnetic resonance imaging, 50:45
 Wechsler Memory Scale, schizophrenia, 50:45
Wisconsin Card Sorting Test
 frontal lobes, regional cerebral blood flow, 50:177
 frontal lobes, single photon emission computed tomography, 50:177
 frontal lobes, task difficulty, 50:177
 regional cerebral blood flow, frontal lobes, 50:177
 regional cerebral blood flow, task difficulty, 50:177
 single photon emission computed tomography, frontal lobes, 50:177
 single photon emission computed tomography, task difficulty, 50:177
 task difficulty, frontal lobes, 50:177
 task difficulty, regional cerebral blood flow, 50:177
 task difficulty, single photon emission computed tomography, 50:177